PlainPill

MOTS-C vs Tirzepatide for energy

Short answer: For energy, more users report improvement with MOTS-C — 83% of 78 reports, versus 44% of 32 for Tirzepatide.

MOTS-C has 0 meta-analyses and 4 randomized trials on PubMed; Tirzepatide has 214 and 132.

Based on 213 reports about MOTS-C and 428 about Tirzepatide. Not medical advice.

MOTS-C
Peptide
Tirzepatide
Medication
Users say it helped49%helped100 reports · high confidence75%helped287 reports · high confidence
Verdict
Mixed
Mostly positive
ResearchCResearch: LimitedAResearch: Strong
Meta-analyses / RCTs0 / 4214 / 132
Mainly used for
Weight loss
% reporting improvement
86% (14)94% (206)
Energy
% reporting improvement
83% (78)44% (32)
Appetite
% reporting improvement
—84% (79)
Performance
% reporting improvement
85% (34)83% (12)
Mood
% reporting improvement
100% (5)63% (27)
Common side effectsinsomnia, injection site, dizziness, jitterinessnausea, fatigue, anhedonia, constipation
Typical dose reportedNot listedNot listed
MOTS-C
What a user said
“Taking these makes me feel wildly energetic all day—zero afternoon slumps, and my endurance during cardio feels bottomless.”
Full MOTS-C profile →
Tirzepatide
Latest review conclusion

This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.

Pharmacol Res, 2021 ↗
What a user said
“Tirzepatide works so well! Do some research in the r/peptides subreddit and the r/tirzepatide subreddit. It's the most effective thing I've ever seen for appetite suppressant.”
Full Tirzepatide profile →

Related comparisons

Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate